Clinical Trial

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-04-08; most recent amendment 2025-11-27.
Status change: Not Yet Recruiting → Recruiting 2024-06-19
Trial Details
NCT Number NCT06362746
Lead Sponsor Supergene, LLC
Conditions Pulmonary Embolism
Enrollment 486 participants
Start Date 2024-05-23
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-05